|View printer-friendly version|
|October 17, 2016 7:01 a.m.|
|Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs|
Chronic Low Back Pain Program Update
Based on these results, Regeneron and Teva plan to design a pivotal
Phase 3 study in chronic low back pain that excludes patients with
advanced osteoarthritis. The companies plan to submit a pivotal program
plan for review with the
Osteoarthritis Pain Program Update
Updated data from the osteoarthritis pain Phase 2/3 study and the chronic low back pain Phase 2b study will be presented at upcoming medical congresses.
“We are making data-driven decisions on Phase 3 fasinumab dosing that we
believe will maximize potential benefit for patients in need, while
minimizing the likelihood of side effects,” said
“We believe fasinumab represents an important potential innovation for
patients with osteoarthritis pain and chronic low back pain who
currently have clear unmet need and limited treatment options,” said
Regeneron and Teva are collaborating on the global development and
commercialization of fasinumab. Under a separate agreement with
Teva's Safe Harbor Statement under the
Regeneron Forward-Looking Statements and Use of
This news release includes forward-looking statements that involve
risks and uncertainties relating to future events and the future
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).
Teva Pharmaceutical Industries Ltd.